Oligoastrocytoma medical therapy: Difference between revisions

Jump to navigation Jump to search
(Mahshid)
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
The predominant therapy for oligoastrocytoma is surgical resection.<ref name="pmid20425038">{{cite journal| author=Pouratian N, Schiff D| title=Management of low-grade glioma. | journal=Curr Neurol Neurosci Rep | year= 2010 | volume= 10 | issue= 3 | pages= 224-31 | pmid=20425038 | doi=10.1007/s11910-010-0105-7 | pmc=PMC2857752 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20425038  }} </ref><ref name="pmid18533376">{{cite journal| author=Chandana SR, Movva S, Arora M, Singh T| title=Primary brain tumors in adults. | journal=Am Fam Physician | year= 2008 | volume= 77 | issue= 10 | pages= 1423-30 | pmid=18533376 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18533376  }} </ref> Adjunctive chemotherapy and radiation are required.<ref name="pmid20425038">{{cite journal| author=Pouratian N, Schiff D| title=Management of low-grade glioma. | journal=Curr Neurol Neurosci Rep | year= 2010 | volume= 10 | issue= 3 | pages= 224-31 | pmid=20425038 | doi=10.1007/s11910-010-0105-7 | pmc=PMC2857752 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20425038  }} </ref><ref name="pmid18533376">{{cite journal| author=Chandana SR, Movva S, Arora M, Singh T| title=Primary brain tumors in adults. | journal=Am Fam Physician | year= 2008 | volume= 77 | issue= 10 | pages= 1423-30 | pmid=18533376 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18533376  }} </ref><ref name=rxcanada>Treatment of mixed gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/mixed-glioma/?region=on. Accessed on October 20, 2015</ref><ref name=rxchemo>Chemotherapeutic drugs in malignant gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/treatment/chemotherapy/?region=on. Accessed on October 20, 2015</ref><ref name="pmid15284265">{{cite journal| author=Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J et al.| title=Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. | journal=J Clin Oncol | year= 2004 | volume= 22 | issue= 15 | pages= 3133-8 | pmid=15284265 | doi=10.1200/JCO.2004.10.169 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15284265  }} </ref><ref name="pmid12107116">{{cite journal| author=Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J et al.| title=Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. | journal=Am J Pathol | year= 2002 | volume= 161 | issue= 1 | pages= 313-9 | pmid=12107116 | doi=10.1016/S0002-9440(10)64183-1 | pmc=PMC1850690 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12107116  }} </ref><ref name="pmid20555079">{{cite journal| author=Stupp R, Tonn JC, Brada M, Pentheroudakis G, ESMO Guidelines Working Group| title=High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | journal=Ann Oncol | year= 2010 | volume= 21 Suppl 5 | issue=  | pages= v190-3 | pmid=20555079 | doi=10.1093/annonc/mdq187 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20555079  }} </ref> Supportive therapy for oligoastrocytoma includes [[anticonvulsants]] and [[corticosteroids]].<ref name=rxcanada>Treatment of mixed gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/mixed-glioma/?region=on. Accessed on October 20, 2015</ref>
The predominant therapy for oligoastrocytoma is surgical resection. Adjunctive chemotherapy and radiation are required. Supportive therapy for oligoastrocytoma includes [[anticonvulsants]] and [[corticosteroids]].


==Medical Therapy==
==Medical Therapy==
Line 10: Line 10:


===Radiotherapy===
===Radiotherapy===
*[[Radiation|Post-operative radiotherapy]] is recommended among all patients who develop oligoastrocytoma.<ref name="pmid20425038">{{cite journal| author=Pouratian N, Schiff D| title=Management of low-grade glioma. | journal=Curr Neurol Neurosci Rep | year= 2010 | volume= 10 | issue= 3 | pages= 224-31 | pmid=20425038 | doi=10.1007/s11910-010-0105-7 | pmc=PMC2857752 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20425038  }} </ref><ref name="pmid18533376">{{cite journal| author=Chandana SR, Movva S, Arora M, Singh T| title=Primary brain tumors in adults. | journal=Am Fam Physician | year= 2008 | volume= 77 | issue= 10 | pages= 1423-30 | pmid=18533376 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18533376  }} </ref><ref name=rxcanada>Treatment of mixed gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/mixed-glioma/?region=on. Accessed on October 20, 2015</ref>
*[[Radiation|Post-operative radiotherapy]] is recommended among all patients who develop oligoastrocytoma.<ref name="pmid20425038">{{cite journal| author=Pouratian N, Schiff D| title=Management of low-grade glioma. | journal=Curr Neurol Neurosci Rep | year= 2010 | volume= 10 | issue= 3 | pages= 224-31 | pmid=20425038 | doi=10.1007/s11910-010-0105-7 | pmc=PMC2857752 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20425038  }} </ref><ref name="pmid18533376">{{cite journal| author=Chandana SR, Movva S, Arora M, Singh T| title=Primary brain tumors in adults. | journal=Am Fam Physician | year= 2008 | volume= 77 | issue= 10 | pages= 1423-30 | pmid=18533376 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18533376  }} </ref><ref name="rxcanada">Treatment of mixed gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/mixed-glioma/?region=on. Accessed on October 20, 2015</ref>
*Radiotherapy may not cure the cancer but can control the tumor, delay recurrence, and increase survival.
*Radiotherapy may not cure the cancer but can control the tumor, delay recurrence, and increase survival.
*[[Radiation|External beam radiation therapy]] is preferred to whole brain radiotherapy.<ref name=rxcanada>Treatment of mixed gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/mixed-glioma/?region=on. Accessed on October 20, 2015</ref>
*[[Radiation|External beam radiation therapy]] is preferred to whole brain radiotherapy.<ref name="rxcanada">Treatment of mixed gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/mixed-glioma/?region=on. Accessed on October 20, 2015</ref>
*It may also be given as the main treatment, if [[surgery]] is not an option.
*It may also be given as the main treatment, if [[surgery]] is not an option.
*External beam radiation therapy is usually administered in standard fractions of 1.8–2 Gy and can reach a total dose in the range of 60 Gy.<ref name="pmid20555079">{{cite journal| author=Stupp R, Tonn JC, Brada M, Pentheroudakis G, ESMO Guidelines Working Group| title=High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | journal=Ann Oncol | year= 2010 | volume= 21 Suppl 5 | issue=  | pages= v190-3 | pmid=20555079 | doi=10.1093/annonc/mdq187 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20555079  }} </ref>
*External beam radiation therapy is usually administered in standard fractions of 1.8–2 Gy and can reach a total dose in the range of 60 Gy.<ref name="pmid20555079">{{cite journal| author=Stupp R, Tonn JC, Brada M, Pentheroudakis G, ESMO Guidelines Working Group| title=High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | journal=Ann Oncol | year= 2010 | volume= 21 Suppl 5 | issue=  | pages= v190-3 | pmid=20555079 | doi=10.1093/annonc/mdq187 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20555079  }} </ref>


===Chemotherapy===
===Chemotherapy===
*[[Chemotherapy]] is indicated as adjuvant therapy for oligoastrocytoma.<ref name="pmid20425038">{{cite journal| author=Pouratian N, Schiff D| title=Management of low-grade glioma. | journal=Curr Neurol Neurosci Rep | year= 2010 | volume= 10 | issue= 3 | pages= 224-31 | pmid=20425038 | doi=10.1007/s11910-010-0105-7 | pmc=PMC2857752 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20425038  }} </ref><ref name="pmid18533376">{{cite journal| author=Chandana SR, Movva S, Arora M, Singh T| title=Primary brain tumors in adults. | journal=Am Fam Physician | year= 2008 | volume= 77 | issue= 10 | pages= 1423-30 | pmid=18533376 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18533376  }} </ref><ref name=rxcanada>Treatment of mixed gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/mixed-glioma/?region=on. Accessed on October 20, 2015</ref>
*[[Chemotherapy]] is indicated as adjuvant therapy for oligoastrocytoma.<ref name="pmid20425038">{{cite journal| author=Pouratian N, Schiff D| title=Management of low-grade glioma. | journal=Curr Neurol Neurosci Rep | year= 2010 | volume= 10 | issue= 3 | pages= 224-31 | pmid=20425038 | doi=10.1007/s11910-010-0105-7 | pmc=PMC2857752 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20425038  }} </ref><ref name="pmid18533376">{{cite journal| author=Chandana SR, Movva S, Arora M, Singh T| title=Primary brain tumors in adults. | journal=Am Fam Physician | year= 2008 | volume= 77 | issue= 10 | pages= 1423-30 | pmid=18533376 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18533376  }} </ref><ref name="rxcanada">Treatment of mixed gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/mixed-glioma/?region=on. Accessed on October 20, 2015</ref>
*[[Temozolomide]] ([[Temodar]]) is the preferred drug for the treatment of oligoastrocytoma.<ref name=rxcanada>Treatment of mixed gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/mixed-glioma/?region=on. Accessed on October 20, 2015</ref><ref name="pmid15284265">{{cite journal| author=Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J et al.| title=Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. | journal=J Clin Oncol | year= 2004 | volume= 22 | issue= 15 | pages= 3133-8 | pmid=15284265 | doi=10.1200/JCO.2004.10.169 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15284265  }} </ref>
*[[Temozolomide]] ([[Temodar]]) is the preferred drug for the treatment of oligoastrocytoma.<ref name="rxcanada">Treatment of mixed gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/mixed-glioma/?region=on. Accessed on October 20, 2015</ref><ref name="pmid15284265">{{cite journal| author=Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J et al.| title=Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. | journal=J Clin Oncol | year= 2004 | volume= 22 | issue= 15 | pages= 3133-8 | pmid=15284265 | doi=10.1200/JCO.2004.10.169 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15284265  }} </ref>
*[[PCV regimen|PCV 3 regimen]] is the preferred combination chemotherapy for oligoastrocytoma.<ref name="pmid12107116">{{cite journal| author=Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J et al.| title=Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. | journal=Am J Pathol | year= 2002 | volume= 161 | issue= 1 | pages= 313-9 | pmid=12107116 | doi=10.1016/S0002-9440(10)64183-1 | pmc=PMC1850690 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12107116  }} </ref>
*[[PCV regimen|PCV 3 regimen]] is the preferred combination chemotherapy for oligoastrocytoma.<ref name="pmid12107116">{{cite journal| author=Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J et al.| title=Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. | journal=Am J Pathol | year= 2002 | volume= 161 | issue= 1 | pages= 313-9 | pmid=12107116 | doi=10.1016/S0002-9440(10)64183-1 | pmc=PMC1850690 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12107116  }} </ref>
**[[CCNU]] is administered on day 1, [[procarbazine]] is administered daily for 14 days beginning on day 8, and [[vincristine]] is administered on days 8 and 29 of each 6-week cycle of therapy.<ref name="pmid7407756">{{cite journal| author=Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ et al.| title=Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. | journal=Cancer Treat Rep | year= 1980 | volume= 64 | issue= 2-3 | pages= 237-44 | pmid=7407756 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7407756  }} </ref>
**[[CCNU]] is administered on day 1, [[procarbazine]] is administered daily for 14 days beginning on day 8, and [[vincristine]] is administered on days 8 and 29 of each 6-week cycle of therapy.<ref name="pmid7407756">{{cite journal| author=Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ et al.| title=Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. | journal=Cancer Treat Rep | year= 1980 | volume= 64 | issue= 2-3 | pages= 237-44 | pmid=7407756 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7407756  }} </ref>
*Other chemotherapeutic drugs that may be used for the treatment of oligoastrocytoma include:<ref name=rxchemo>Chemotherapeutic drugs in malignant gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/treatment/chemotherapy/?region=on. Accessed on October 20, 2015</ref>
*Other chemotherapeutic drugs that may be used for the treatment of oligoastrocytoma include:<ref name="rxchemo">Chemotherapeutic drugs in malignant gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/treatment/chemotherapy/?region=on. Accessed on October 20, 2015</ref>
**[[Carmustine]]
**[[Carmustine]]
**[[Cisplatin]]
**[[Cisplatin]]
Line 29: Line 29:
**[[Irinotecan]]
**[[Irinotecan]]
**[[Methotrexate]] ([[intrathecal|intrathecally]])
**[[Methotrexate]] ([[intrathecal|intrathecally]])
*If oligoastrocytoma is unresponsive to the chemotherapeutic drugs used in earlier treatments or if it recurs, other drugs that may be used include:<ref name=rxchemo>Chemotherapeutic drugs in malignant gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/treatment/chemotherapy/?region=on. Accessed on October 20, 2015</ref>
*If oligoastrocytoma is unresponsive to the chemotherapeutic drugs used in earlier treatments or if it recurs, other drugs that may be used include:<ref name="rxchemo">Chemotherapeutic drugs in malignant gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/treatment/chemotherapy/?region=on. Accessed on October 20, 2015</ref>
**[[Tamoxifen]]  
**[[Tamoxifen]]
**[[Carboplatin]]
**[[Carboplatin]]
**[[Etoposide]]
**[[Etoposide]]
*The advanced mode of delivery of chemotherapeutic drugs to the brain include:<ref name=rxchemo>Chemotherapeutic drugs in malignant gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/treatment/chemotherapy/?region=on. Accessed on October 20, 2015</ref>
*The advanced mode of delivery of chemotherapeutic drugs to the brain include:<ref name="rxchemo">Chemotherapeutic drugs in malignant gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/treatment/chemotherapy/?region=on. Accessed on October 20, 2015</ref>
**Intraventrical chemotherapy
**Intraventrical chemotherapy
**Interstitial chemotherapy
**Interstitial chemotherapy
Line 39: Line 39:


===Supportive treatment===
===Supportive treatment===
Supportive therapy for oligoastrocytoma includes [[anticonvulsants]] and [[corticosteroids]], which focuses on relieving symptoms and improving the patient’s neurologic function. The types of supportive therapy that may be used are:<ref name=rxcanada>Treatment of mixed gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/mixed-glioma/?region=on. Accessed on October 20, 2015</ref>
Supportive therapy for oligoastrocytoma includes [[anticonvulsants]] and [[corticosteroids]], which focuses on relieving symptoms and improving the patient’s neurologic function. The types of supportive therapy that may be used are:<ref name="rxcanada">Treatment of mixed gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/mixed-glioma/?region=on. Accessed on October 20, 2015</ref>
*[[Anticonvulsants]]
*[[Anticonvulsants]]
**These drugs prevent [[seizures]].
**These drugs prevent [[seizures]].

Revision as of 03:11, 23 October 2019

Oligoastrocytoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Oligoastrocytoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Oligoastrocytoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Oligoastrocytoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Oligoastrocytoma medical therapy

CDC on Oligoastrocytoma medical therapy

Oligoastrocytoma medical therapy in the news

Blogs on Oligoastrocytoma medical therapy

Directions to Hospitals Treating Glioma

Risk calculators and risk factors for Oligoastrocytoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]

Overview

The predominant therapy for oligoastrocytoma is surgical resection. Adjunctive chemotherapy and radiation are required. Supportive therapy for oligoastrocytoma includes anticonvulsants and corticosteroids.

Medical Therapy

The medical therapy of oligodendroglioma includes:

Radiotherapy

  • Post-operative radiotherapy is recommended among all patients who develop oligoastrocytoma.[1][2][3]
  • Radiotherapy may not cure the cancer but can control the tumor, delay recurrence, and increase survival.
  • External beam radiation therapy is preferred to whole brain radiotherapy.[3]
  • It may also be given as the main treatment, if surgery is not an option.
  • External beam radiation therapy is usually administered in standard fractions of 1.8–2 Gy and can reach a total dose in the range of 60 Gy.[4]

Chemotherapy

Supportive treatment

Supportive therapy for oligoastrocytoma includes anticonvulsants and corticosteroids, which focuses on relieving symptoms and improving the patient’s neurologic function. The types of supportive therapy that may be used are:[3]

References

  1. 1.0 1.1 Pouratian N, Schiff D (2010). "Management of low-grade glioma". Curr Neurol Neurosci Rep. 10 (3): 224–31. doi:10.1007/s11910-010-0105-7. PMC 2857752. PMID 20425038.
  2. 2.0 2.1 Chandana SR, Movva S, Arora M, Singh T (2008). "Primary brain tumors in adults". Am Fam Physician. 77 (10): 1423–30. PMID 18533376.
  3. 3.0 3.1 3.2 3.3 3.4 Treatment of mixed gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/mixed-glioma/?region=on. Accessed on October 20, 2015
  4. Stupp R, Tonn JC, Brada M, Pentheroudakis G, ESMO Guidelines Working Group (2010). "High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Ann Oncol. 21 Suppl 5: v190–3. doi:10.1093/annonc/mdq187. PMID 20555079.
  5. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J; et al. (2004). "Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions". J Clin Oncol. 22 (15): 3133–8. doi:10.1200/JCO.2004.10.169. PMID 15284265.
  6. Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J; et al. (2002). "Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets". Am J Pathol. 161 (1): 313–9. doi:10.1016/S0002-9440(10)64183-1. PMC 1850690. PMID 12107116.
  7. Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ; et al. (1980). "Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors". Cancer Treat Rep. 64 (2–3): 237–44. PMID 7407756.
  8. 8.0 8.1 8.2 Chemotherapeutic drugs in malignant gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/treatment/chemotherapy/?region=on. Accessed on October 20, 2015


Template:WikiDoc Sources